A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3) Editorial


Authors: Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Jin Leei, W.; Goetze, T. O.; Van Cutsem, E.; Paulson, A. S.; Bekaii-Saab, T.; Pant, S.; Hubner, R. A.; Xiao, Z.; Chen, H.; Benzaghou, F.; O’Reilly, E. M.
Title: A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Keywords: controlled study; survival analysis; fluorouracil; diarrhea; drug safety; nonhuman; gemcitabine; paclitaxel; comparative study; pancreas cancer; follow up; prospective study; anemia; leukopenia; thrombocytopenia; survival time; folinic acid; diagnosis; nausea and vomiting; oxaliplatin; ductal carcinoma; pancreas metastasis; human; article; irinotecan sucrosofate; treatment guideline; plain language summary
Journal Title: Future Oncology
Volume: 21
Issue: 7
ISSN: 1479-6694
Publisher: Future Medicine  
Date Published: 2025-01-01
Start Page: 765
End Page: 774
Language: English
DOI: 10.1080/14796694.2025.2458458
PUBMED: 39935331
PROVIDER: scopus
PMCID: PMC11916414
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eileen O'Reilly
    780 O'Reilly